Antibody fusion proteins: effective adjuvants of protein vaccination
View Patent ↗The present invention provides methods of use of various antibody-immunostimulant fusion proteins as adjuvants of antigenic protein vaccinations to elicit humoral and/or cellular immune responses in vaccinated subjects. Compositions which include these fusion proteins and innate and/or exogenous antigenic proteins are also provided.
1. An ex vivo pharmaceutical composition comprising: an antibody-immunostimulant fusion protein having an antibody domain and an immunostimulant domain, a disease-related antigen, one or more antigen presenting cells, and a pharmaceutically acceptable carrier or a pharmaceutically acceptable excipient,
wherein the fusion protein acts as an effective adjuvant of the disease-related antigen;
wherein the antibody-immunostimulant fusion protein comprises antibody specificity against the antigen;
wherein the antibody domain comprises an intact antibody, comprising two light chains and two heavy chains, or an antibody fragment, which fragment is selected from the group consisting of an Fab domain, an Fab′ domain, an F(ab′) 2 domain, an scFv domain, and an F(ab) 2 domain; and,
wherein the immunostimulant domain comprises an immunostimulant selected from the group consisting of IL-2, IL-12, and GM-CSF.
2. The composition of claim 1 , wherein the antibody-immunostimulant fusion protein comprises a linker.
3. The composition of claim 1 , wherein the antibody domain of the antibody-immunostimulant fusion protein comprises an antibody specific for a HER2/neu antigen.
4. The composition of claim 1 , wherein the antibody domain of the antibody-immunostimulant fusion protein comprises an antibody specific for a tumor antigen.
5. The composition of claim 1 , wherein the antibody-immunostimulant fusion protein comprises a domain selected from the group consisting of: IgG, IgA, IgE, IgM, IgD, IgG1, IgG2, and IgG3.
6. The composition of claim 1 , wherein the antigen comprises HER2/neu, HER2/neu shed from a tumor cell, or a fragment of HER2/neu or HER2/neu shed from a tumor cell.
7. The composition of claim 1 , wherein the antigen comprises an antigen arising from a subject, arising from a disease state within the subject, or arising from a disease related organism within the subject.
8. The composition of claim 7 , wherein the disease state within the subject is caused by a tumor.
9. The composition of claim 7 , wherein the antigen comprises a tumor antigen.
10. The composition of claim 1 , wherein the antigen comprises an exogenous antigen.
11. The composition of claim 10 , wherein the exogenous antigen comprises an antigen substantially identical to an antigen arising from a disease state within a subject or from a disease related organism within the subject.
12. The composition of claim 1 , wherein the composition comprises a plurality of the antigen and a plurality of the antibody-immunostimulant fusion protein.
13. The composition of claim 1 , wherein the antigen comprises one or more antigen chosen from the group consisting of: a soluble antigen, a soluble antigen bound to a matrix, an insoluble antigen bound to a matrix, an insoluble aggregate of antigens, an antigen comprising one or more epitopes, a nonviable cell-associated antigen, a nonviable organism-associated antigen, or an antigen conjugated with a liposome.
14. The composition of claim 12 , wherein the members of the plurality of the antibody-immunostimulant fusion protein are substantially saturated by members of the plurality of the antigen.
15. The composition of claim 1 , wherein the immunostimulant domain comprises an immunostimulant selected from the group consisting of IL-12 and GM-CSF.
16. The composition of claim 15 , wherein the antibody domain of the antibody-immunostimulant fusion protein comprises an antibody specific for a HER2/neu antigen and wherein the antigen comprises HER2/neu, HER2/neu shed from a tumor cell, or a fragment of HER2/neu or HER2/neu shed from a tumor cell.
17. An ex vivo pharmaceutical composition comprising: an antibody-immunostimulant fusion protein having an antibody domain and an immunostimulant domain, a HER2/neu antigen, one or more antigen presenting cells, and a pharmaceutically acceptable carrier or a pharmaceutically acceptable excipient,
wherein the fusion protein acts as an effective adjuvant of the HER2/neu antigen;
wherein the antibody-immunostimulant fusion protein comprises antibody specificity against the HER2/neu antigen;
wherein the antibody domain comprises IgG3; and,
wherein the immunostimulant domain comprises an immunostimulant selected from the group consisting of IL-2, IL-12, and GM-CSF.
18. The composition of claim 17 , wherein the immunostimulant domain comprises an immunostimulant selected from the group consisting of IL-12 and GM-CSF.
19. The composition of claim 1 or claim 17 , wherein the antigen presenting cell is a dendritic cell.